Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.01
>-AU$0.01(-8.33%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-8.33%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume169.96K
Average Volume (3M)687.55K
Market Cap
AU$6.12M
Enterprise ValueAU$5.85M
Total Cash (Recent Filing)AU$1.71M
Total Debt (Recent Filing)AU$2.52M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.09%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding612,154,100
10 Day Avg. Volume1,094,223
30 Day Avg. Volume687,550
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong 2026 revenue rebound indicates that the business can regain commercial momentum after periods of contraction. If this recovery persists, greater scale could improve operating leverage, support product investment, and strengthen the company’s ability to convert demand into more durable earnings.
Positive Cash FlowPositive operating and free cash flow in the latest year is an important improvement for a company with continuing accounting losses. Sustained cash generation would reduce reliance on external funding, provide greater flexibility for operations, and help support development activity over the next several quarters.
Narrower Net LossA materially smaller net loss shows progress toward reducing the gap between revenue and total costs. While this does not yet establish sustainable profitability, continued improvement could preserve cash, reduce financing pressure, and create a clearer path toward eventual operating break-even.
Bears Say
Persistent LossesPersistent net, EBIT, and EBITDA losses indicate that the current business model has not yet demonstrated sustainable profitability. Continued operating deficits can consume resources, constrain reinvestment, and leave future growth dependent on maintaining revenue recovery or securing additional financing.
Weaker Balance SheetThe combination of a compressed equity base and elevated debt-to-equity materially reduces the balance-sheet cushion available to shareholders and creditors. For a biotechnology company with recurring losses, this weaker financial position can limit flexibility and increase sensitivity to future funding needs.
Volatile Financial PerformanceLarge swings in revenue and cash generation make the company’s underlying financial trajectory difficult to sustain and forecast. The history of recurring cash burn means that the latest improvement may reverse if revenue normalizes or costs rise, increasing pressure on liquidity and capital allocation.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$6.12M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 128 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of 9.09%. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 612,154,100 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:ACR Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$149.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―